secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001193125-23-145682
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks closes transfer of zanidatamab program to Jazz; amends collaboration agreement
--------------------------------------------------------------------------------

- Jazz acquired 100% of Zymeworks subsidiary ZZI and certain assets; Zymeworks transferred employees and contracts for zanidatamab program.
- Under amended agreement, Jazz is solely responsible for development, regulatory, and commercial activities; costs borne directly by Jazz.
- Zymeworks will continue to supply zanidatamab for clinical sites performing the program.
- Original financial terms unchanged; some costs expected to be unrecoverable, to be finalized by mid-2023.
- Jazz's nonexclusive license expanded to research and develop Licensed Products outside the Territory for the Program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523145682/0001193125-23-145682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523145682/d481028d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-145682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer